The Radiculopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Radiculopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Radiculopathy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Radiculopathy - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Radiculopathy and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Radiculopathy by six companies/universities/institutes. The top development phase for Radiculopathy is discovery with four drugs in that stage. The Radiculopathy pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Radiculopathy pipeline products market are: Quiver Bioscience, Novassay and Lateral Pharma.

The key targets in the Radiculopathy pipeline products market include Sodium Channel Protein Type 10 Subunit Alpha (Peripheral Nerve Sodium Channel 3 or Voltage Gated Sodium Channel Subunit Alpha Nav1.8 or SCN10A), Sodium Channel Protein Type 9 Subunit Alpha (Neuroendocrine Sodium Channel or Peripheral Sodium Channel 1 or Voltage Gated Sodium Channel Subunit Alpha Nav1.7 or SCN9A), and Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1).

The key mechanisms of action in the Radiculopathy pipeline product include Sodium Channel Protein Type 9 Subunit Alpha (Neuroendocrine Sodium Channel or Peripheral Sodium Channel 1 or Voltage Gated Sodium Channel Subunit Alpha Nav1.7 or SCN9A) Blocker with two drugs in Discovery. The Radiculopathy pipeline products include three routes of administration with the top ROA being Intravenous and five key molecule types in the Radiculopathy pipeline products market including Antisense Oligonucleotide, and Gene Therapy.

Radiculopathy overview

Nerve roots emerge from the spinal cord and travel between the vertebrae to the peripheral areas of the body. When these nerve roots become pinched or damaged, the resulting symptoms are called radiculopathy. The pinched nerve can occur at different areas along the spin: cervical, thoracic, or lumbar.

For a complete picture of Radiculopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.